文献速递白血病造血干细胞移植与细胞治疗

Ph+慢性髓性白血病中HLA不相合亲缘供者异基因造血细胞移植与其他供者类型的比较:EBMT慢性恶性肿瘤工作组的回顾性分析

Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT.
PubMed 文献 · Br J Haematol · 2024-04-05

该研究基于EBMT登记库1686例2012至2019年首次接受异基因造血细胞移植的CML患者,按供者类型比较结局,重点分析HLA不相合亲缘供者(MMRD)。4年总生存各组无显著差异(p=0.21),无复发生存有显著差异(p=0.03);多因素分析显示MMRD与植入时间延长和植入失败风险升高相关,但总生存、无复发生存和GvHD发生率与其他供者类型无统计学差异证据。

要点

  • 4年总生存MRD 61%、MMRD 56%、MUD 63%、MMUD 59%(p=0.21)。
  • 4年无复发生存MRD 48%、MMRD 42%、MUD 52%、MMUD 46%(p=0.03)。
  • 多因素分析中MMRD较MRD或MUD植入时间更长、植入失败风险更高。

核心结论

  • 多因素分析无统计学证据表明MMRD与其他供者类型在总生存、无复发生存和GvHD发生率上存在差异。
  • MMRD使用与植入时间延长和植入失败风险升高相关(对比MRD或MUD)。

研究设计与样本

  • 欧洲血液与骨髓移植学会(EBMT)登记库回顾性研究,纳入1686例2012至2019年首次接受异基因造血细胞移植的CML患者。
  • 移植时中位年龄46岁(IQR 36-55);疾病状态为第一次慢性期43%、第二次慢性期或更晚27%、加速期12%、急变期18%。
  • 供者类型为全相合亲缘供者(MRD)39.2%、MMRD 8.1%、全相合无关供者(MUD)40.2%、不相合无关供者(MMUD)12.6%。

主要发现

  • 4年总生存MRD 61%、MMRD 56%、MUD 63%、MMUD 59%(p=0.21)。
  • 4年无复发生存MRD 48%、MMRD 42%、MUD 52%、MMUD 46%(p=0.03)。
  • 4年累积复发率MRD 33%、MMRD 37%、MUD 27%、MMUD 30%(p=0.07)。
  • 4年非复发死亡MRD 19%、MMRD 21%、MUD 21%、MMUD 24%(p=0.21)。
  • 4年无GvHD/无复发生存MRD 16%、MMRD 18%、MUD 22%、MMUD 15%(p=0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic haematopoietic cell transplantation (allo-HCT) remains an option for tyrosine kinase inhibitor-resistant chronic myeloid leukaemia (CML) in first chronic phase (CP1) and high-risk patients with advanced disease phases. In this European Society for Blood and Marrow Transplantation (EBMT) registry-based study of 1686 CML patients undergoing first allo-HCT between 2012 and 2019, outcomes were evaluated according to donor type, particularly focusing on mismatched related donors (MMRDs). Median age at allo-HCT was 46 years (IQR 36-55). Disease status was CP1 in 43%, second CP (CP2) or later in 27%, accelerated phase in 12% and blast crisis in 18%. Donor type was matched related (MRD) in 39.2%, MMRD in 8.1%, matched unrelated (MUD) in 40.2%, and mismatched unrelated (MMUD) in 12.6%. In 4 years, overall survival (OS) for MRD, MMRD, MUD and MMUD was 61%, 56%, 63% and 59% (p = 0.21); relapse-free survival (RFS) was 48%, 42%, 52% and 46% (p = 0.03); cumulative incidence of relapse (CIR) was 33%, 37%, 27% and 30% (p = 0.07); non-relapse mortality (NRM) was 19%, 21%, 21% and 24% (p = 0.21); and graft-versus-host disease (GvHD)-free/relapse-free survival (GRFS) was 16%, 18%, 22% and 15% (p = 0.05) respectively. On multivariate analysis, MMRD use associated with longer engraftment times and higher risk of graft failure compared to MRD or MUD. There was no statistical evidence that MMRD use associated with different OS, RFS and incidence of GvHD compared to other donor types.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Onida F, Gras L, Ge J, et al. Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT. Br J Haematol. 2024. PMID: 38577874. doi:10.1111/bjh.19448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。